People getting a subcutaneous implantable cardioverter-defibrillator (S-ICD) did fine skipping the defibrillation test after ...

AstraZeneca’s SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus ...

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...

Subcutaneous pembrolizumab has now been administered to the first patients in the UK following its nationwide rollout across ...

AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

Sarclisa (isatuximab) has been approved in the US since 2020, initially for relapsed/refractory multiple myeloma before ...

Amlitelimab is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis.

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. The FDA was supposed to dole out a verdict on subcutaneous Tecentriq ...

AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) ...

Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.